Search Results - "Gramatzki, D."

Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study by Gramatzki, D., Roth, P., Rushing, E.J., Weller, J., Andratschke, N., Hofer, S., Korol, D., Regli, L., Pangalu, A., Pless, M., Oberle, J., Bernays, R., Moch, H., Rohrmann, S., Weller, M.

“…The vascular endothelial growth factor antibody bevacizumab (Avastin®), received approval for the treatment of recurrent glioblastoma in many countries…”
Get full text

The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway by Silginer, M, Burghardt, I, Gramatzki, D, Bunse, L, Leske, H, Rushing, E J, Hao, N, Platten, M, Weller, M, Roth, P

“…Glioblastoma is the most common and aggressive form of intrinsic brain tumor. Transforming growth factor (TGF)-β represents a central mediator of the malignant…”
Get full text

DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development by Binder, H, Willscher, E, Loeffler-Wirth, H, Hopp, L, Jones, D T W, Pfister, S M, Kreuz, M, Gramatzki, D, Fortenbacher, E, Hentschel, B, Tatagiba, M, Herrlinger, U, Vatter, H, Matschke, J, Westphal, M, Krex, D, Schackert, G, Tonn, J C, Schlegel, U, Steiger, H-J, Wick, W, Weber, R G, Weller, M, Loeffler, M

“…Diffuse lower WHO grade II and III gliomas (LGG) are slowly progressing brain tumors, many of which eventually transform into a more aggressive type. LGG is…”
Get full text

Aryl hydrocarbon receptor inhibition downregulates the TGF-β Smad pathway in human glioblastoma cells by Gramatzki, D, Pantazis, G, Schittenhelm, J, Tabatabai, G, Köhle, C, Wick, W, Schwarz, M, Weller, M, Tritschler, I

“…The dioxin/aryl hydrocarbon receptor (AhR) is a transcription factor, which has been attributed a role in human cancerogenesis, cell cycle progression and…”
Get full text

NDRG1 prognosticates the natural course of disease in WHO grade II glioma by Blaes, J., Weiler, M., Sahm, F., Hentschel, B., Osswald, M., Czabanka, M., Thomé, C. M., Schliesser, M. G., Pusch, S., Luger, S., Winkler, F., Radbruch, A., Jugold, M., Simon, M., Steinbach, J. P., Schackert, G., Tatagiba, M., Westphal, M., Tonn, J. C., Gramatzki, D., Pietsch, T., Hartmann, C., Glimm, H., Vajkoczy, P., von Deimling, A., Platten, M., Weller, M., Wick, W.

“…There is a lack of relevant prognostic and predictive factors in neurooncology besides mutation of isocitrate dehydrogenase 1 , codeletion of 1p/19q and…”
Get full text

P11.14.B PROGNOSTIC ASSOCIATIONS OF STEROID USE IN GLIOBLASTOMA: A POPULATION-BASED STUDY by Abdel Moneim, Y, Weller, M, Gramatzki, D

“…Abstract BACKGROUND Steroids are widely used in brain tumor patients to control symptoms related to tumor and cerebral edema. A possible detrimental effect of…”
Get full text

P10.19.B An immunotoxin targeting CD317 for the treatment of glioblastoma by Gramatzki, D, Weiss, T, Hänsch, L, Silginer, M, Rushing, E J, Roth, P, Gramatzki, M, Peipp, M, Weller, M

“…Abstract Background CD317 is an interferon-inducible cell surface receptor expressed in several solid cancer types. HM1.24-ETA’ is a small immunotoxin with a…”
Get full text

P16.04.A THE PROGNOSTIC ROLE OF VENTRICULAR SIZE AND ITS DYNAMICS IN PATIENTS WITH LEPTOMENINGEAL METASTASIS FROM SOLID TUMORS by Le Rhun, E, Devos, P, Seystahl, K, Jongen, J, Gramatzki, D, Roth, P, van den Bent, M J, Regli, L, Brandsma, D, Weller, M

“…Abstract BACKGROUND Hydrocephalus is a common radiological sign in patients with leptomeningeal metastasis (LM) from solid tumors and can be assessed using the…”
Get full text

P06.08.A CLINICAL OUTCOME AND TRANSLATIONAL INSIGHTS FROM A PHASE I/II TRIAL WITH THE TUMOR-TARGETING ANTIBODY-CYTOKINE FUSION PROTEIN L19TNF FOR PATIENTS WITH RECURRENT GLIOBLASTOMA by Weiss, T, Hemmerle, T, Gramatzki, D, Hottinger, A F, Roth, P, Schulz, D, Bodenmiller, B, Bink, A, Neri, D, Weller, M

“…Abstract BACKGROUND Treatment options for recurrent glioblastoma are limited and there is a need for novel effective therapies. Cytokine-based therapies are…”
Get full text

PL03.3.A Development and characterization of CD317-specific CAR T cells as an innovative immunotherapeutic strategy against glioblastoma by Hänsch, L, Peipp, M, Myburgh, R, Silginer, M, Weiss, T, Gramatzki, D, Vasella, F, Manz, M, Weller, M, Roth, P

“…Abstract BACKGROUND Due to the limited success of existing therapies for gliomas, innovative therapeutic options are urgently needed. Chimeric antigen receptor…”
Get full text

P20.09.A CLINICAL, PATHOLOGICAL AND MOLECULAR DISEASE CHARACTERISTICS OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT by Le Rhun, E, Bink, A, Felsberg, J, Gramatzki, D, Brandner, S, Benhamida, J K, Wick, A, Tonn, J C, Mohme, M, Tabatabai, G, Capper, D, Snuderl, M, Razis, E, Ronellenfitsch, M, Neidert, N, Ng, H, Pohl, U, Bale, T A, Quach, S, Rieger, D, Schüller, U, Drüschler, K, Healy, E, Graham, M, Paine, S M L, Medici, V, Sievers, P, Schrimpf, D, Wick, W, Sahm, F, Reifenberger, G, von Deimling, A, Weller, M

“…Abstract BACKGROUND Diffuse hemispheric glioma, histone 3 (H3) G34-mutant, is a pediatric-type diffuse high-grade glioma newly defined in the World Health…”
Get full text

P11.45 Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models by von Achenbach, C, Weller, M, Kaulich, K, Gramatzki, D, Zacher, A, Fabbro, D, Reifenberger, G, Szabó, E

“…Abstract BACKGROUND Molecular genetic aberrations in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway…”
Get full text

360O Telomerase reverse transcriptase (TERT) promoter mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: Is there a link? by Weller, M., Gramatzki, D., Felsberg, J., Hentschel, B., Wolter, M., Schackert, G., Westphal, M., Regli, L., Thon, N., Tatagiba, M., Wick, W., Schlegel, U., Krex, D., Roth, P., Rushing, E., Pietsch, T., von Deimling, A., Sabel, M., Loeffler, M., Reifenberger, G.

Get full text

P11.21.A LONG-TERM SURVIVAL WITH IDH WILDTYPE GLIOBLASTOMA: FIRST RESULTS FROM THE ETERNITY BRAIN TUMOR FUNDERS’ COLLABORATIVE CONSORTIUM (EORTC 1419) by Weller, M, Felsberg, J, Gramatzki, D, Le Rhun, E, Clarke, J, Soffietti, R, Wick, W, Chinot, O, Ducray, F, Roth, P, McDonald, K, Hau, P, Hottinger, A F, Reijneveld, J, Schnell, O, Marosi, C, Glantz, M, Darlix, A, Lombardi, G, Krex, D, Glas, M, Reardon, D A, van den Bent, M J, Lefranc, F, Herrlinger, U, Razis, E, Carpentier, A F, Phillips, S, Rudà, R, Wick, A, Tabouret, E, Meyronet, D, Maurage, C, Rushing, E, Rapkins, R

“…Abstract BACKGROUND Median survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years…”
Get full text

OS2.2 Chemotherapy for spinal gliomas in adults by Gramatzki, D, Felsberg, J, Bähr, O, Hentschel, B, Westphal, M, Schackert, G, Tonn, J C, Herrlinger, U, Löffler, M, Pietsch, T, Steinbach, J, Reifenberger, G, Roth, P, Weller, M

“…Abstract BACKGROUND Chemotherapy is a treatment option in patients diagnosed with anaplastic gliomas or glioblastomas of the spinal cord, or with recurrent…”
Get full text

P14.108 Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma by Seystahl, K, Hentschel, B, Loew, S, Gramatzki, D, Felsberg, J, Herrlinger, U, Westphal, M, Schackert, G, Thon, N, Schlegel, U, Tatagiba, M, Pietsch, T, Reifenberger, G, Löffler, M, Wick, W, Weller, M

“…Abstract BACKGROUND The use of alkylating chemotherapy versus bevacizumab for recurrent glioblastoma remains controversial. Here we tested the hypothesis that…”
Get full text

P01.30 In vivo effects of isoform-specific inhibition of TGF-β3 in glioblastoma by Seystahl, K., Burghardt, I., Gramatzki, D., Schneider, H., Papachristodoulou, A., Hasenbach, K., Frei, K., Janicot, M., Roth, P., Weller, M.

“…Introduction: Transforming growth factor (TGF)-β has been considered a therapeutic target in glioblastoma since decades. However, despite promising preclinical…”
Get full text

The aryl hydrocarbon receptor links integrin signaling to the TGF-[beta] pathway by Silginer, M, Burghardt, I, Gramatzki, D, Bunse, L, Leske, H, Rushing, E J, Hao, N, Platten, M, Weller, M, Roth, P

“…Glioblastoma is the most common and aggressive form of intrinsic brain tumor. Transforming growth factor (TGF)-[beta] represents a central mediator of the…”
Get full text

Leptomeningeal Disease by Piña, Y., Gramatzki, D., Forsyth, P., Lee, E. Q., Le Rhun, Emilie

Get full text

OS01.6 Glioblastoma in the era of bevacizumab: an epidemiological study in the Canton of Zurich, Switzerland by Gramatzki, D., Roth, P., Rushing, E. J., Weller, J., Andratschke, N., Hofer, S., Regli, L., Oberle, J., Rohrmann, S., Weller, M.

“…Background: The vascular endothelial growth factor antibody, bevacizumab (Avastin®), received approval for the treatment of recurrent glioblastoma in…”
Get full text